Study shows similar incidence of rare blood clots with Pfizer and AstraZeneca COVID vaccines

London — A study by researchers at Oxford University in England suggests the number of people who experience blood clots after getting the coronavirus vaccine made by American pharmaceutical giants Pfizer and Moderna is very similar to the number who get the rare condition after a shot of the drug produced by Oxford's vaccine institute in partnership with AstraZeneca.

Another key finding of the research, revealed Thursday as a "pre-print" study which has yet to be reviewed by other scientists, was that the risk of experiencing a blood clot in the brain was about 95 times higher for people who contract COVID-19 than in the general population. That's yet another serious health threat associated with the disease, and one the scientists hoped would boost confidence in all of the major vaccines currently available in the Western world, as their research suggests the drugs carry a significantly lower threat of blood clotting than the disease they've been proven to fend off.